- $123.31m
- -$27.94m
- 44
- 39
- 61
- 45
Annual cashflow statement for Sagimet Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -11.4 | -24.4 | -30.5 | -27.9 | -45.6 |
| Depreciation | |||||
| Non-Cash Items | 0.879 | 2.79 | 1.79 | 5.09 | 4.18 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.075 | -0.055 | 4.21 | -0.978 | -1.05 |
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -10.4 | -21.7 | -24.5 | -23.8 | -42.4 |
| Other Investing Cash Flow Items | 0.02 | 0 | -32 | 12.6 | -61.7 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0.02 | 0 | -32 | 12.6 | -61.7 |
| Financing Cash Flow Items | — | -1.25 | -0.085 | 86.2 | -1.04 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 68.9 | 9.74 | -0.073 | 86.2 | 105 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 58.5 | -12 | -56.6 | 75 | 0.701 |